PRME stock forecast, quote, news & analysis
Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression... Show more
Why Prime Medicine (PRME) Stock Is Up +17% in the Last 30 Days
Key Takeaways
- Prime Medicine (PRME) shares rose roughly 17% over the past 30 days, climbing from about $3.13 to a recent close of $3.67.
- The advance was fueled by clinical and regulatory milestones, including FDA clearance of the PM647 IND for alpha-1 antitrypsin deficiency and first-patient dosing in the Phase 1/2 PM577a trial for Wilson disease.
- Over the trailing quarter, the stock is up about 24%, although trading has remained volatile for this early-stage gene-editing developer.
- Analysts maintain a consensus Buy rating with an average price target near $7.11, well above recent trading levels, even as the company remains pre-revenue with substantial research spending.
- Prime Medicine ended June 2026 with $108.8 million in cash and investments, which management expects to fund operations into 2027.
- Prime Editing remains clinically unproven at scale; near-term value depends heavily on early clinical data anticipated in 2027.
- For additional context on this ticker's Price Targets, Earnings, and Forecast, explore the linked pages.
- Explore Trending AI Robots to see which automated trading strategies are currently active.
Prime Medicine (PRME) Company Overview and Market Position
Prime Medicine is a Cambridge, Massachusetts-based biotechnology company focused on delivering one-time, potentially curative genetic therapies using its proprietary Prime Editing platform. The technology is designed to rewrite DNA at a precise location without introducing the double-strand breaks associated with earlier CRISPR-Cas9 approaches, with the goal of correcting the root cause of genetic disease rather than managing its symptoms.
The company's lead programs include PM577a for Wilson disease and PM647 for alpha-1 antitrypsin deficiency (AATD), both liver-directed in vivo therapies, as well as PM359, an ex vivo program for chronic granulomatous disease (CGD). Prime Medicine also maintains research collaborations with partners including Bristol Myers Squibb (BMY) and the Cystic Fibrosis Foundation. Investors follow the stock for its differentiated editing technology and a pipeline spanning liver, lung, and immunology and oncology, while weighing those opportunities against the company's early-stage profile and financing needs.
Prime Medicine (PRME) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, PRME shares advanced approximately 17%, rising from a closing level near $3.13 to a recent close of $3.67. The move was not linear: the stock slipped to an intraday low around $2.90 in late September before rallying through October as clinical news flow improved.
The broader quarterly picture is similarly constructive. Compared with a closing price near $2.97 roughly three months earlier, the stock is up about 24%. That multi-month gain reflects a steady accumulation of regulatory clearances and trial-initiation milestones, even as the shares continue to trade well below their 52-week high and remain subject to sharp swings typical of clinical-stage biotechnology names.
What Drove PRME Stock Price in the Last 30 Days
The recent advance was driven primarily by tangible pipeline progress. On September 24, Prime Medicine announced that the U.S. Food and Drug Administration had cleared its Investigational New Drug application for PM647, an in vivo Prime Editor for AATD. The clearance enabled the company to move toward a global Phase 1/2 study, initially in adults with lung-related manifestations of the disease.
Shortly afterward, in early October, the company dosed the first patient in its global Phase 1/2 trial of PM577a for Wilson disease, marking the first clinical evaluation of its in vivo Prime Editing approach and the first clinical study in its liver franchise. The FDA also granted Rare Pediatric Disease designation to PM577 for Wilson disease, adding a regulatory milestone to the narrative.
Supportive analyst commentary reinforced the move. H.C. Wainwright reiterated a Buy rating with an $8 price target in early October, while LifeSci Capital maintained a Buy rating with a $6 target, contributing to a broader consensus Buy rating and an average price target near $7.11. The combination of regulatory momentum and constructive sell-side views helped lift sentiment despite the company's pre-revenue status.
What Drove PRME Stock Performance Over the Last Quarter
The quarterly rally rests on a broader progression of milestones. During the summer, Prime Medicine secured New Zealand clinical authorization for PM577a, followed by FDA clearance of the PM577a IND in July, establishing a global Phase 1/2 program for Wilson disease. The company also reported second-quarter results that showed a narrowed net loss of $42.1 million, down from $52.6 million a year earlier, as research and administrative expenses declined.
Progress on the PM359 program added further support. PM359 has received Regenerative Medicine Advanced Therapy (RMAT), Fast Track, Orphan Drug, and Rare Pediatric Disease designations, with the company continuing regulatory engagement toward a potential Biologics License Application in the first half of 2027. A favorable arbitration resolution with Beam Therapeutics affirmed Prime Medicine's rights to PM647, removing an overhang. Collectively, these developments shifted the narrative from platform validation toward clinical execution across multiple programs.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of the platform's top-performing automated trading strategies. Tickeron offers hundreds of AI-powered trading bots that monitor thousands of tickers, but only the most relevant and consistently strong performers are featured in this section. The bots differ in strategy, trading timeframe, and performance metrics, giving users a range of approaches to review rather than a single one-size-fits-all system. For traders interested in data-driven, systematic approaches to the market, exploring this page can provide a useful view of which automated strategies are currently generating attention.
PRME Stock Forecast Drivers: What Investors Should Watch Next
The next phase of PRME's story will center on execution and early data. Initial clinical results for both PM577a and PM647 are anticipated in 2027, and any signs of safety, editing efficiency, or biological activity could be significant for sentiment. A planned Biologics License Application for PM359 in the first half of 2027 represents another key milestone.
Financing remains a critical factor. With $108.8 million in cash as of June 30, 2026 and a quarterly cash burn of roughly $40 million, investors will watch how the company manages its runway and any future capital raises. Broader conditions also matter, including investor appetite for speculative biotech, interest-rate dynamics, and developments across the gene-editing sector. As with all clinical-stage companies, outcomes are uncertain, and early milestones do not guarantee commercial success.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
PRME's RSI Indicator recovers from overbought zone
The 10-day RSI Oscillator for PRME moved out of overbought territory on October 30, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 17 instances where the indicator moved out of the overbought zone. In 16 of the 17 cases the stock moved lower in the days that followed. This puts the odds of a move down at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on PRME as a result. In 56 of 67 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 84%.
The Moving Average Convergence Divergence Histogram (MACD) for PRME turned negative on November 09, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 35 similar instances when the indicator turned negative. In 32 of the 35 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PRME declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
PRME broke above its upper Bollinger Band on October 27, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
PRME moved above its 50-day moving average on October 15, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for PRME crossed bullishly above the 50-day moving average on October 09, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 85%.
The 50-day moving average for PRME moved above the 200-day moving average on October 29, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Following a +11.94% 3-day Advance, the price is estimated to grow further. Considering data from situations where PRME advanced for three days, in 159 of 194 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
The Aroon Indicator entered an Uptrend today. In 99 of 114 cases where PRME Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 87%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 27 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.422) is normal, around the industry mean (3.498). P/E Ratio (-4.429) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (128.205) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 39 (best 1 - 100 worst), indicating steady price growth. PRME’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 91 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 95 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PRME’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology